Y513 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ ºÎ±³°¨½Å°æÂ÷´ÜÁ¦ [Ç×Äݸ°Á¦ ¹× Ç×¹«½ºÄ«¸°Á¦] ¹× ¿¬Ãà¾ðÁ¦Á¦ | Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, NEC causing adverse effects in therapeutic use |
|
Y513 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÆÄÆĺ£¸° | Papaverine causing adverse effects in therapeutic use |
|
Y514 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¿ì¼¼¼º º£¾ËÆÄ-¾Æµå·¹³ª¸° ¼ö¿ëü ÀÛ¿ëÁ¦ | Predominantly ¥á-adrenoreceptor agonists, NEC causing adverse effects in therapeutic use |
|
Y514 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸¶Å¸¶ó¹Ì³î | Metaraminol causing adverse effects in therapeutic use |
|
Y515 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¿ì¼¼¼º º£Å¸-¾Æµå·¹³ª¸° ¼ö¿ëü ÀÛ¿ëÁ¦ | Predominantly ¥â-adrenoreceptor agonists, NEC causing adverse effects in therapeutic use |
|
Y516 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¾ËÆÄ-¾Æµå·¹³ª¸°¼ö¿ëü ±æÇ×Á¦ | ¥á-adrenoreceptor antagonists,NEC causing adverse effects in therapeutic use |
|
Y517 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº º£Å¸-¾Æµå·¹³¯¸°¼ö¿ëü ±æÇ×Á¦ | ¥â-adrenoreceptor antagonists, NEC causing adverse effects in therapeutic use |
|
Y518 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃß¼º ÀÛ¿ë ¹× ¾Æµå·¹³¯¸°-´º·Ð-Â÷´ÜÁ¦ | Centrally acting and adrenergic-neuron-blocking agents, NEC causing adverse effects in therapeutic use |
|
Y519 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ | Other and unspecified drugs primarily affecting the autonomic nervous system causing adverse effects in therapeutic use |
|
Y519 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ËÆÄ ¹× º£Å¸ ¾Æµå·¹³ª¸° ¼ö¿ëü ¸ðµÎ¸¦ ÀÚ±ØÇÏ´Â ¾àÁ¦ | Drugs stimulating both ¥á- and ¥â-adrenoreceptors causing adverse effects in therapeutic use |
|
Y52 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ½ÉÇ÷°ü°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use |
|
Y520 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½ÉÀåÀÚ±Ø ¹è´çü ¹× À¯»çÀÛ¿ë ¾à¹° | Cardiac-stimulant glycosides and drugs of similar action causing adverse effects in therapeutic use |
|
Y521 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ä®½·Ã¤³ÎÂ÷´ÜÁ¦ | Calcium-channel blockers causing adverse effects in therapeutic use |
|
Y522 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Ç׺ÎÁ¤¸ÆÁ¦ | Other antidysrhythmic drugs, NEC causing adverse effects in therapeutic use |
|
Y523 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº °ü»óµ¿¸ÆÈ®ÀåÁ¦ | Coronary vasodilators, NEC causing adverse effects in therapeutic use |
|
Y523 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â µðÇǸ®´Ù¸ô | Dipyridamole causing adverse effects in therapeutic use |
|
Y524 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò¾ïÁ¦Á¦ | Angiotensin-converting-enzyme inhibitors causing adverse effects in therapeutic use |
|
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Ç×°íÇ÷¾ÐÁ¦ | Other antihypertensive drugs, NEC causing adverse effects in therapeutic use |
|
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Å©·Î´Ïµò | Clonidine causing adverse effects in therapeutic use |
|
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸¾Æ³×Ƽµò | Guanethidine causing adverse effects in therapeutic use |
|